Search results
Results from the WOW.Com Content Network
Sun Pharmaceutical Industries Ltd. was established by Dilip Shanghvi in 1983 in Calcutta, West Bengal with five psychiatry products and a two-person marketing team. Today it is ranked number one in share of prescriptions with 12 classes of doctors in India and a market leader in Psychiatry, Neurology, Cardiology, Orthopaedics, Gastroenterology, Nephrology, Diabetology, Dermatology, Urology ...
He named his venture Sun Pharmaceutical Industries. The unit, located in Vapi in his native state of Gujarat, a short drive away from Mumbai, produced exactly one psychiatry drug. [1] However, the business soon picked up, thanks to Shanghvi's acumen and energy, and by 1997, Sun Pharma was even able to acquire Caraco Pharma, an American company ...
In 2008, Japanese pharmaceutical company Daiichi Sankyo acquired a controlling share in Ranbaxy [2] and in 2014, Sun Pharma acquired 100% of Ranbaxy in an all-stock deal. The Sun Pharma acquisition brought all new management to Ranbaxy, which had been laden with controversy (see Controversies below). Sun is the world's fifth largest specialty ...
In the lawsuit filed at the United States District Court for New Jersey, Mayne Pharma accused its rival of violating all 20 Orange Book-listed patents linked to IMVEXXY - a vaginal insert aimed at ...
In 2010, Sun Pharmaceuticals of India acquired a majority stake in the company. [6] On 22 March 2012, the company's shares were re-listed on the NYSE. In 2013, Sun Pharmaceuticals attempted to buy the remaining shares in the company (it owns 69% stake), but as the company's financial performance improved, shareholders rejected the offer and the company remained publicly listed.
Gujarat has become a hub for the pharmaceutical industry, with several established companies such as Torrent Pharmaceuticals, Zydus Lifesciences, Cadila Pharmaceuticals, Alembic Pharmaceuticals, Sun Pharma, Claris, Intas Pharmaceuticals, and Dishman Pharmaceuticals having operations in the state.
The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. [1] India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports.
Upgrade to a faster, more secure version of a supported browser. It's free and it only takes a few moments: